Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021
SINGAPORE, April 22, 2021 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on its clinical development activities.
Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: “ASLAN made significant progress in the fourth quarter of 2020 and that momentum has carried over into 2021. After completing recruitment of the third cohort in our multiple ascending dose trial for ASLAN004 in the fourth quarter, we announced positive interim data supportive of its potential as a novel, first-in-class antibody targeting IL-13R with a differentiated efficacy and safety profile in atopic dermatitis. We are on track to complete enrolment of the expansion cohort with an additional 27 patients by mid-2021 and anticipate reporting topline data in the third quarter of 2021. At the same time, we are continuing to prepare for our Phase 2b study, which we expect to initiate in the second half of 2021. ASLAN is in a strong financial position with the necessary resources to fund its development activities to achieve important value creating milestones for shareholders.”
Fourth quarter 2020 and recent business highlights
Clinical development
ASLAN004
ASLAN003
Corporate updates
Anticipated upcoming milestones
Fourth quarter 2020 financial highlights
Full year 2020 financial highlights
ASLAN Pharmaceuticals Limited CONSOLIDATED BALANCE SHEETS (In U.S. Dollars) |
||||||||
December 31, 2019 (audited) |
December 31, 2020 (audited) |
|||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash and cash equivalents | $ | 22,203,031 | $ | 14,324,371 | ||||
Other receivables | – | 528,841 | ||||||
Prepayments | 68,923 | 511,208 | ||||||
Financial assets at fair value through profit or loss | – | 137,926 | ||||||
Total current assets | 22,271,954 | 15,502,346 | ||||||
NON-CURRENT ASSETS | ||||||||
Financial assets at fair value through profit or loss | 68,256 | – | ||||||
Financial assets at fair value through other comprehensive income | 132,160 | – | ||||||
Property, plant and equipment | 38,333 | 13,387 | ||||||
Right-of-use assets | 727,866 | 462,550 | ||||||
Intangible assets | 2,845 | 160 | ||||||
Refundable deposits | 108,076 | 103,307 | ||||||
Total non-current assets | 1,077,536 | 579,404 | ||||||
TOTAL ASSETS | $ | 23,349,490 | $ | 16,081,750 | ||||
LIABILITIES AND EQUITY | ||||||||
CURRENT LIABILITIES | ||||||||
Trade payables | $ | 1,871,843 | $ | 2,319,558 | ||||
Other payables | 3,246,842 | 4,280,409 | ||||||
Current portion of long-term borrowing | – | 2,900,971 | ||||||
Current portion of long-term borrowing from related parties | – | 617,912 | ||||||
Lease liabilities – current | 264,543 | 271,624 | ||||||
Financial liabilities at fair value through profit or loss | – | 267,000 | ||||||
Total current liabilities | 5,383,228 | 10,657,474 | ||||||
NON-CURRENT LIABILITIES | ||||||||
Financial liabilities at fair value through profit or loss | 262,350 | – | ||||||
Long-term borrowings | 17,065,305 | 15,183,421 | ||||||
Long-term borrowing from related parties | 566,176 | – | ||||||
Lease liabilities – non-current | 490,835 | 281,149 | ||||||
Other non-current liabilities | 184,870 | 111,990 | ||||||
Total non-current liabilities | 18,569,536 | 15,576,560 | ||||||
Total liabilities | 23,952,764 | 26,234,034 | ||||||
EQUITY ATTRIBUTABLE TO STOCKHOLDERS OF THE COMPANY | ||||||||
Ordinary shares | 61,366,844 | 61,826,237 | ||||||
Capital surplus | 116,495,710 | 123,582,460 | ||||||
Accumulated deficits | (179,484,825 | ) | (195,682,714 | ) | ||||
Other reserves | (55,084 | ) | (178,948 | ) | ||||
Total equity attributable to stockholders of the Company | (1,677,355 | ) | (10,452,965 | ) | ||||
NON-CONTROLLING INTERESTS | 1,074,081 | 300,681 | ||||||
Total equity | (603,274 | ) | (10,152,284 | ) | ||||
TOTAL LIABILITIES AND EQUITY | $ | 23,349,490 | $ | 16,081,750 | ||||
ASLAN Pharmaceuticals Limited CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In U.S. Dollars, other than shares or share data) |
||||||||||||||||
Three Months Ended December 31 (unaudited) |
Twelve Months Ended December 31 (audited) |
|||||||||||||||
2019 | 2020 | 2019 | 2020 | |||||||||||||
NET REVENUE | $ | – | $ | – | $ | 3,000,000 | $ | – | ||||||||
COST OF REVENUE | 17,741 | – | (407,259 | ) | – | |||||||||||
GROSS PROFIT | 17,741 | – | 2,592,741 | – | ||||||||||||
OPERATING EXPENSES | ||||||||||||||||
General and administrative expenses | (3,258,197 | ) | (3,033,267 | ) | (8,511,699 | ) | (7,169,177 | ) | ||||||||
Research and development expenses | (2,702,625 | ) | (2,881,623 | ) | (16,586,617 | ) | (9,314,120 | ) | ||||||||
Total operating expenses | (5,960,822 | ) | (5,914,890 | ) | (25,098,316 | ) | (16,483,297 | ) | ||||||||
Impairment loss on intangible assets | (23,073,400 | ) | – | (23,073,400 | ) | – | ||||||||||
LOSS FROM OPERATIONS | (29,016,481 | ) | (5,914,890 | ) | (45,578,975 | ) | (16,483,297 | ) | ||||||||
NON-OPERATING INCOME AND EXPENSES | ||||||||||||||||
Interest income | 6,193 | 154 | 150,610 | 592 | ||||||||||||
Other income | – | 888,046 | – | 888,046 | ||||||||||||
Other gains and losses | (289,268 | ) | (321,729 | ) | (327,558 | ) | (129,299 | ) | ||||||||
Finance costs | (293,110 | ) | (326,178 | ) | (901,612 | ) | (1,247,331 | ) | ||||||||
Total non-operating income and expenses | (576,185 | ) | 240,293 | (1,078,560 | ) | (487,992 | ) | |||||||||
LOSS BEFORE INCOME TAX | (29,592,666 | ) | (5,674,597 | ) | (46,657,535 | ) | (16,971,289 | ) | ||||||||
INCOME TAX EXPENSE | (12,712 | ) | (230,853 | ) | (408,002 | ) | – | |||||||||
NET LOSS FOR THE PERIOD | (29,605,378 | ) | (5,905,450 | ) | (47,065,537 | ) | (16,971,289 | ) | ||||||||
OTHER COMPREHENSIVE LOSS | ||||||||||||||||
Items that will not be reclassified subsequently to profit or loss: |
||||||||||||||||
Unrealized loss on investments in equity instruments at fair value through other comprehensive income |
(46,038 | ) | (49,533 | ) | (55,084 | ) | (123,864 | ) | ||||||||
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD | $ | (29,651,416 | ) | $ | (5,954,983 | ) | $ | (47,120,621 | ) | $ | (17,095,153 | ) | ||||
NET LOSS ATTRIBUTABLE TO: | ||||||||||||||||
Stockholders of the Company | $ | (29,555,808 | ) | $ | (5,715,998 | ) | $ | (47,015,967 | ) | $ | (16,197,889 | ) | ||||
Non-controlling interests | (49,570 | ) | (189,452 | ) | (49,570 | ) | (773,400 | ) | ||||||||
$ | (29,605,378 | ) | $ | (5,905,540 | ) | $ | (47,065,537 | ) | $ | (16,971,289 | ) | |||||
TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO: | ||||||||||||||||
Stockholders of the Company | $ | (29,601,846 | ) | $ | (5,765,531 | ) | $ | (47,071,051 | ) | $ | (16,321,753 | ) | ||||
Non-controlling interests | (49,570 | ) | (189,452 | ) | (49,570 | ) | (773,400 | ) | ||||||||
$ | 29,651,416 | ) | $ | (5,954,983 | ) | $ | (47,120,621 | ) | $ | (17,095,153 | ) | |||||
LOSS PER ORDINARY SHARE | ||||||||||||||||
Basic and diluted | $ | (0.18 | ) | $ | (0.03 | ) | $ | (0.29 | ) | $ | (0.08 | ) | ||||
LOSS PER EQUIVALENT ADS | ||||||||||||||||
Basic and diluted | $ | (0.90 | ) | $ | (0.15 | ) | $ | (1.45 | ) | $ | (0.40 | ) | ||||
Weighted-average number of ordinary shares in the computation of basic loss per ordinary share |
168,753,687 | 199,066,161 | 162,392,602 | 192,226,528 | ||||||||||||
Each ADS represents five ordinary shares. | ||||||||||||||||
Media and IR contacts | |
Emma Thompson Spurwing Communications Tel: +65 6751 2021 Email: ASLAN@spurwingcomms.com |
Robert Uhl Westwicke Partners Tel: +1 858 356 5932 Email: robert.uhl@westwicke.com |
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease. For additional information please visit www.aslanpharma.com.
Forward looking statements
This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the “Company”). These forward-looking statements may include, but are not limited to, statements regarding the Company’s business strategy and clinical development plans; the Company’s plans to develop and commercialise ASLAN004 and ASLAN003; the safety and efficacy of ASLAN004 and ASLAN003; the Company’s plans and expected timing with respect to clinical trials and clinical trial results for ASLAN004 and ASLAN003; the Company’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for ASLAN004 and ASLAN003; the potential for ASLAN004 as a novel, first-in-class antibody targeting IL-13R with a differentiated efficacy and safety profile in atopic dermatitis; and the Company’s belief that its cash and cash equivalents will be sufficient to fund operations into 2023. The Company’s estimates, projections and other forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic on the Company’s business and the global economy; general market conditions; changes in the competitive landscape; and the Company’s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company’s US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company’s Annual Report on Form 20-F filed with the US Securities and Exchange Commission on April 16, 2020.
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN…
BOUCHERVILLE, Québec, June 28, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL, LSL.DB)…
SALINAS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL;…
MINNEAPOLIS, MN, US, June 28, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC: PETV, PETVW),…
BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or…
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a…